People say these peptides hurt them. Their stories are muffled in MAHA’s push for medical freedom.

“There are millions of success stories with these peptides, but no one wants to believe that this wrecks some of our lives.”

By
Amy Maxmen
October 13, 2026
14 min

Kff Health News

Objective:

The article examines reports of adverse experiences after BPC-157 use and the debate over expanding access to experimental peptides, including the FDA advisory panel’s recommendation concerning six peptides.

Approach:

Reported experiences: The article recounts accounts from people who say they experienced symptoms after taking BPC-157, including Dylan Meetze’s report of fatigue, anxiety, and twitching.
Evidence and policy: It summarizes an unpublished analysis of electronic health records, FDA scientists’ concerns, and a July advisory-panel vote on six experimental peptides.

Key Findings:

BPC-157 and many other experimental peptides have not undergone clinical trials establishing whether they are safe or effective, although influencers promote them for various conditions.
An unpublished analysis of millions of de-identified health records found that more than 1,000 people had told doctors they used BPC-157 since 2020.
FDA scientists said evidence was insufficient to show that six peptides improved any condition and raised potential risks including liver damage and allergic reactions.
An FDA advisory panel voted to recommend adding six peptides, including BPC-157, to the 503A Bulks List, which would permit specialized pharmacies to make them for human use if the FDA adopts the recommendation. The FDA had not issued a final decision at the time of the article.
People posting online described symptoms after peptide use; those accounts do not establish that the peptides caused the symptoms.

Interpretation:

The article reports a conflict between calls to expand access in the name of medical freedom and concerns from researchers that limited safety and efficacy evidence leaves consumers exposed to risk and may reduce incentives for clinical trials.

Limitations:

The health-record analysis had not been published in a peer-reviewed journal.
Reported adverse experiences are personal accounts and do not establish that peptides caused the symptoms.
The article describes a pending FDA decision; the advisory-panel vote was not a final agency determination.